



09-20-04

1614

CERTIFICATE OF MAILING BY "EXPRESS MAIL" (37 CFR 1.10)			Docket No. 2972-86588	
Applicant(s): Meryl J. Squires				
Application No. 10/084,759	Filing Date February 26, 2002	Examiner Dwayne C. Jones	Customer No. 24828	Group Art Unit 1614
Invention: Antimicrobial Prevention And Treatment of Human Immunodeficiency Virus And Other Infectious Diseases				
<div style="text-align: center;"></div>				
I hereby certify that the following correspondence:				
<div style="border: 1px solid black; padding: 10px; min-height: 40px;">Information Disclosure Statement</div>				
<i>(Identify type of correspondence)</i>				
is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on				
<div style="display: flex; justify-content: space-between;"><div><u>September 17, 2004</u> <i>(Date)</i></div><div><u>Aric Benard</u> <i>(Typed or Printed Name of Person Mailing Correspondence)</i></div></div> <div style="display: flex; justify-content: space-between; margin-top: 20px;"><div></div><div><u></u> <i>(Signature of Person Mailing Correspondence)</i></div></div> <div style="display: flex; justify-content: space-between; margin-top: 20px;"><div></div><div><u>EL 995604264 US</u> <i>("Express Mail" Mailing Label Number)</i></div></div>				
Note: Each paper must have its own certificate of mailing.				

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**FEE TRANSMITTAL
for FY 2004**

Effective 10/01/2003. Patent fees are subject to annual revision.

☐ Applicant claims small entity status. See 37 CFR 1.27**TOTAL AMOUNT OF PAYMENT (\$)** **\$180.00****Complete if Known**

Application Number	10/084,759
Filing Date	February 26, 2002
First Named Inventor	Meryl J. Squires
Examiner Name	Dwayne C. Jones
Art Unit	1614
Attorney Docket No.	2972-86588

METHOD OF PAYMENT (check all that apply)☒ Check ☐ Credit card ☐ Money Order ☐ Other ☐ None☐ Deposit Account:Deposit
Account
Number

23-0920

Deposit
Account
Name

Welsh & Katz, Ltd.

The Director is authorized to: (check all that apply)

☐ Charge fee(s) indicated below ☐ Credit any overpayments☒ Charge any additional fee(s) or any underpayment of fee(s)☐ Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.**FEE CALCULATION****1. BASIC FILING FEE**

Large Entity		Small Entity		Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)		
1001	770	2001	385	Utility filing fee	
1002	340	2002	170	Design filing fee	
1003	530	2003	265	Plant filing fee	
1004	770	2004	385	Reissue filing fee	
1005	160	2005	80	Provisional filing fee	
SUBTOTAL (1)				(\$)	

2. EXTRA CLAIM FEES FOR UTILITY AND

Extra Claims		Fee from below		Fee Paid
Total Claims	<input type="text"/> -20** = <input type="text"/> 0	X	<input type="text"/>	= <input type="text"/> 0.00
Independent Claims	<input type="text"/> - 3** = <input type="text"/> 0	X	<input type="text"/>	= <input type="text"/> 0.00
Multiple Dependent			<input type="text"/>	= <input type="text"/>

Large Entity		Small Entity		Fee Description
Fee Code	Fee (\$)	Fee Code	Fee (\$)	
1202	18	2202	9	Claims in excess of 20
1201	86	2201	43	Independent claims in excess of 3
1203	290	2203	145	Multiple dependent claim, if not paid
1204	86	2204	43	** Reissue independent claims over original patent
1205	18	2205	9	** Reissue claims in excess of 20 and over original patent

SUBTOTAL (2) (\$)

**or number previously paid, if greater; For Reissues, see above

FEE CALCULATION (continued)**3. ADDITIONAL FEES**

Large Entity		Small Entity		Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)		
1051	130	2051	65	Surcharge - late filing fee or oath	
1052	50	2052	25	Surcharge - late provisional filing fee or cover sheet	
1053	130	1053	130	Non - English specification	
1812	2,520	1812	2,520	For filing a request for <i>ex parte</i> reexamination	
1804	920*	1804	920*	Requesting publication of SIR prior to Examiner action	
1805	1,840*	1805	1,840*	Requesting publication of SIR after Examiner action	
1251	110	2251	55	Extension for reply within first month	
1252	420	2252	210	Extension for reply within second month	
1253	950	2253	475	Extension for reply within third month	
1254	1,480	2254	740	Extension for reply within fourth month	
1255	2,010	2255	1,005	Extension for reply within fifth month	
1401	330	2401	165	Notice of Appeal	
1402	330	2402	165	Filing a brief in support of an appeal	
1403	290	2403	145	Request for oral hearing	
1451	1,510	1451	1,510	Petition to institute a public use proceeding	
1452	110	2452	55	Petition to revive - unavoidable	
1453	1,330	2453	665	Petition to revive - unintentional	
1501	1,330	2501	665	Utility issue fee (or reissue)	
1502	480	2502	240	Design issue fee	
1503	640	2503	320	Plant issue fee	
1460	130	1460	130	Petitions to the Commissioner	
1807	50	1807	50	Processing fee under 37 CFR § 1.17(q)	
1806	180	1806	180	Submission of Information Disclosure Statement	180.00
8021	40	8021	40	Recording each patent assignment per property (times number of properties)	
1809	770	2809	385	Filing a submission after final rejection (37 CFR § 1.129(a))	
1810	770	2810	385	For each additional invention to be examined (37 CFR § 1.129(b))	
1801	770	2801	385	Request for Continued Examination (RCE)	
1802	900	1802	900	Request for expedited examination of a design application	

Other fee (specify)

*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$)

\$180.00

SUBMITTED BY

Name (Print/Type)

Thomas W. Tolpin

Registration No.
(Attorney/Agent)

27,600

Complete (if applicable)

Telephone

(312) 655-1500

Signature

Thomas W. Tolpin

Date

September 17, 2004

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PATENT

UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:	Meryl J. Squires)	Group Art Unit:	1614
)		
Serial No:	10/084,759)	Primary Examiner:	Dwayne C. Jones
)		
Filed:	February 26, 2002)	Attorney Docket No:	2972-86588
)		
For:	Antimicrobial Prevention)		
	And Treatment of Human)		
	Immunodeficiency Virus And Other)		
	Infectious Diseases)	Confirmation No.	4483
)		
)		

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-0001

Dear Sir:

The fee of \$180 for submission of an Information Disclosure Statement under 37 CFR 1.17(p) is paid by check attached hereto.

The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Account No. 23-0920.

The patents listed below were located in the following supplementary European search report of a European patent application corresponding to the above-identified application of the applicant. The patents listed below generally relate to the subject matter of the invention, but do not fairly teach or suggest the claimed Antimicrobial Prevention And Treatment of Human Immunodeficiency Virus And Other Infectious Diseases. Copies of the listed patents are enclosed for consideration by the Primary Examiner.

09/20/2004 EAREGAY1 00000089 10084759

01 FC:1806

180.00 (P)


1. Communication of March 22, 2004, Supplemental European Search Report and Annex to the European Search Report on European Patent Application No. EP 98913086.

2. Lomapharm, Rudolf Lohman GmbH KG Pharmazeutische Fabrik: Wagner, Hildebert, Prof., Dr., Bauer, Rudolph, Dr., Ott, Holger, German Patent No. DE 3522075 A1, issued January 1, 1987 with Abstract.

3. Birzer, Michael, German Patent No. DE 3533563 A1, issued March 26, 1987 with Abstract.

4. Stclair Pty Ltd.: Warwick Deane Raymont, Australian Patents Act 1990 Complete Specification for a Petty Patent Original No. 679162, original application number 71904/96, dated February 21, 1997, pertains to Therapeutic Compositions.

Respectfully submitted,

A handwritten signature in black ink, reading "Thomas W. Tolpin", is written over a horizontal line.

Thomas W. Tolpin
Registration Number 27,600
Attorney for Applicant

Address:
Welsh & Katz
120 S. Riverside Plaza, 22nd Floor
Chicago, Illinois 60606
Phone: (312) 655-1500
Fax: (312) 655-1501
September 17, 2004

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

10/24/2001 W&K Substitute for Form PTO-SB/08A, which is a US PTO
Substitute for form 1449A/PTO and 1449B/PTO**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number	10/084,759
Filing Date	February 26, 2002
First Named Inventor	Meryl J. Squires
Art Unit	1614
Examiner Name	Dwayne C. Jones
Attorney Docket Number	2972-86588

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
		DE 3522075 A1	01-01-1987	Lomapharm, Rudolf Lohman GmbH KG Pharmazeutische Fabrik		X
		DE 3533563 A1	03-26-1987	Birzer, Michael		X
		AU 679162 Original Appln. No. 71904/96	02-21-1997	Stolair Pty Ltd.		X

OTHER ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
		Communication of March 22, 2004, Supplemental European Search Report and Annex to the European Search Report on European Patent Application No. EP 98913086.	X

Examiner Signature	Date Considered
-----------------------	--------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

The PTO did not receive the following
listed Items(s) FOR